ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SHR-4597

A development code. Also written as “SHR4597”.

Its studies are mostly in Asthma, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Apr 16, 20252 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine21 open or runningphase 2since Apr 16, 2025Apr 23, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 23, 2024First study: phase 1 study in Healthy SubjectsFirst studyNCT06385964 · 62 enrolled · China
  2. Apr 16, 2025Phase 2 study in AsthmaNCT06940700 · 60 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06940700Asthma · China2Not yet recruitingOct 202560
NCT06385964Healthy Subjects · China1CompletedFeb 19, 202562

How it is read

Names in the registry

  • “SHR-4597”, 1 entry
  • “SHR4597”, 1 entry

Codes read as this program: SHR4597.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.